2.2.2»ùÒò²¶»ñ·¨
»ùÒò²¶»ñ·¨ÊÇ×î½ü·¢Õ¹ÆðÀ´µÄÀûÓÃËæ»ú²åÈëÍ»±ä½øÐлùÒòÇóýµÄÐÂÐÍ·½·¨£¬ÆäÔÀí¿É¼ûͼ6¡£Í¨³£»ùÒò²¶»ñÔØÌ廹°üÀ¨Ò»¸öÎÞÆô¶¯×ӵı¨µÀ»ùÒò£¬Í¨³£ÊÇneo »ùÒò£¬neo »ùÒò²åÈëµ½ES ϸ°ûȾɫÌå×éÖУ¬²¢ÀûÓò¶»ñ»ùÒòµÄת¼µ÷¿ØÔª¼þʵÏÖ±í´ïµÄES ¿Ë¡¿ÉÒÔºÜÈÝÒ×µØÔÚº¬G418 µÄÑ¡ÔñÅàÑø»ùÖÐɸѡ³öÀ´£¬´ÓÀíÂÛÉϽ²£¬ÔÚÑ¡ÔñÅàÑø»ùÖдæ»îµÄ¿Ë¡Ӧ¸Ã100£¥µØº¬ÓÐÖалùÒò¡£ÖалùÒòµÄÐÅÏ¢¿ÉÒÔͨ¹ýɸѡ±ê¼Ç»ùÒò²àÒícDNA»òȾɫÌå×éÐòÁзÖÎöÀ´»ñµÃ[13]
2.2.3»ùÒò²¶»ñ·¨µÄÓÅȱµã
Ó󣹿·½·¨½øÐлùÒòÇóýÑо¿ÐèºÄ·Ñ´óÁ¿µÄʱ¼äºÍÈËÁ¦£¬Ñо¿Õß±ØÐëÕë¶Ô°ÐλµãÔÚȾɫÌå×éÎÄ¿âÖÐɸѡÏà¹ØµÄȾɫÌå×é¿Ë¡£¬»æÖÆÏàÓ¦µÄÎïÀíͼÆ×£¬¹¹½¨ÌØÒìÐԵĻùÒòÇóýÔØÌåÒÔ¼°É¸Ñ¡ÖаÐES ϸ°ûµÈ£¬Í¨³£Ò»¸ö»ùÒòÌÞ³ý´¿ºÏ×ÓСÊóµÄ»ñµÃÐèÒªÒ»Äê»ò¸ü³¤µÄʱ¼ä¡£Ãæ¶ÔÈËÀà»ùÒò×鼯»®²úÉú³öÀ´µÄ¾Þ´óµÄ¹¦ÄÜδ֪µÄÒÅ´«ÐÅÏ¢£¬´«Í³µÄ»ùÒòÇóý·½·¨ÏÔµÃÓÐЩÁ¦²»´ÓÐÄ¡£Òò´Ë£¬»ùÒò²¶»ñ·¨Ó¦Ô˶øÉú£¬ÀûÓûùÒò²¶»ñ¿ÉÒÔ½¨Á¢Ò»¸öЯ´øËæ»ú²åÈëÍ»±äµÄES ϸ°û¿â£¬½ÚÊ¡´óÁ¿É¸Ñ¡È¾É«Ìå×éÎÄ¿âÒÔ¼°¹¹½¨ÌØÒì´ò°ÐÔØÌåµÄ¹¤×÷¼°·ÑÓ㬸üÓÐЧºÍ¸üѸËٵؽøÐÐСÊóȾɫÌå×éµÄ¹¦ÄÜ·ÖÎö¡£
´Ë·½·¨µÄȱµãÊÇÖ»ÄÜÌÞ³ýÔÚEs ϸ°ûÖбí´ïµÄ»ùÒò£®µ¥ÖÖµÄϸ°ûÀàÐÍÖбí´ïµÄ»ùÒòÊýĿԼΪI04£¬ÏÖÔڵĻùÒò²¶»ñÔØÌå´ÓÀíÂÛÉÏÀ´½²Ó¦ÄÜÌÞ³ýËùÓÐÔÚESϸ°û±í´ïµÄ»ùÒò£¬Òò´Ë£¬ÔÚES ϸ°ûÖнøÐлùÒò²¶»ñ»¹ÊÇ´óÓпÉΪµÄ¡£ÓûùÒò²¶»ñ·¨½øÐлùÒòÌÞ³ýµÄÁíÒ»¸öȱµãÊÇÎÞ·¨¶Ô»ùÒò½øÐо«Ï¸µÄÒÅ´«ÐÞÊΣ¬
2.3.RNAiÒýÆðµÄ»ùÒòÇóý¡£
ÓÉÓÚÉÙÁ¿µÄË«Á´RNA¾ÍÄÜ×è¶Ï»ùÒòµÄ±í´ï£¬²¢ÇÒÕâÖÖЧӦ¿ÉÒÔ´«µÝµ½×Ó´úϸ°ûÖÐ,ËùÒÔRNAiµÄ·´Ó¦¹ý³ÌÒ²¿ÉÒÔÓÃÓÚ»ùÒòÇóý¡£½üÄêÀ´£¬Ô½À´Ô½¶àµÄ»ùÒòÇóý²ÉÓÃÁËRNAiÕâÖÖ¸üΪ¼òµ¥·½±ãµÄ·½·¨¡£[13-15]
2.3.1 RNAi×è¶Ï»ùÒò±í´ïµÄ»úÀí
Ë«Á´RNA½øÈëϸ°ûºó£¬Äܹ»ÔÚDicerøµÄ×÷ÓÃϱ»Áѽâ³ÉsiRNA£¬¶øÁíÒ»·½ÃæË«Á´RNA»¹ÄÜÔÚRdRP £¨ÒÔRNAΪģ°åÖ¸µ¼RNAºÏ³ÉµÄ¾ÛºÏøRNA-directed RNA
polymerase£¬RdRP£©µÄ×÷ÓÃÏÂ×ÔÉíÀ©Ôöºó£¬ÔÙ±»DicerøÁѽâ³ÉsiRNA¡£SiRNAµÄË«Á´½â¿ª±ä³Éµ¥Á´£¬²¢ºÍijЩµ°°×Ðγɸ´ºÏÎArgonaute2ÊÇĿǰΨһÒÑÖªµÄ²ÎÓ븴ºÏÎïÐγɵĵ°°×¡£´Ë¸´ºÏÎïͬÓësiRNA»¥²¹µÄmRNA½áºÏ£¬Ò»·½ÃæÊ¹mRNA±»RNAøÁѽ⣬ÁíÒ»·½ÃæÒÔSiRNA×÷ΪÒýÎÒÔmRNAΪģ°å£¬ÔÚRdRP×÷ÓÃϺϳɳömRNAµÄ»¥²¹Á´¡£½á¹ûmRNAÒ²±ä³ÉÁËË«Á´RNA£¬ËüÔÚDicerøµÄ×÷ÓÃÏÂÒ²±»Áѽâ³ÉsiRNA¡£ÕâЩÐÂÉú³ÉµÄsiRNAÒ²¾ßÓÐÓÕ·¢RNAiµÄ×÷Óã¬Í¨¹ýÕâ¸ö¾ÛºÏøÁ´Ê½·´Ó¦£¬Ï¸°ûÄÚµÄsiRNA´ó´óÔö¼Ó£¬ÏÔÖøÔö¼ÓÁ˶ԻùÒò±í´ïµÄÒÖÖÆ¡£´Ó21µ½23¸öºËÜÕËáµÄsiRNAµ½¼¸°Ù¸öºËÜÕËáµÄË«Á´RNA¶¼ÄÜÓÕ·¢RNAi£¬µ«³¤µÄË«Á´RNA×è¶Ï»ùÒò±í´ïµÄЧ¹ûÃ÷ÏÔÇ¿Óڶ̵ÄË«Á´RNA[13]¡£
2.3.2 RNAi»ùÒòÇóýµÄÓŵ㼰ӦÓÃ
¢Ù.±ÈÓÃÍ¬Ô´ÖØ×é·¨¸ü¼Ó¼ò±ã£¬ÖÜÆÚ´ó´óËõ¶Ì¡£
¢Ú.¶ÔÓÚ²¸È鶯ÎÈç¶ÔÓÚһЩÇóýºóСÊóÔÚÅß̥ʱ¾Í»áËÀÍöµÄ»ùÒò£¬¿ÉÒÔÔÚÌåÍâÅàÑøµÄϸ°ûÖÐÀûÓÃRNAi¼¼ÊõÑо¿ËüµÄ¹¦ÄÜ¡£
¢Û.ÓÉÓÚRNAiÄܸßÐ§ÌØÒìµÄ×è¶Ï»ùÒòµÄ±í´ï£¬Ëü³ÉΪÑо¿ÐźŴ«µ¼Í¨Â·µÄÁ¼ºÃ¹¤¾ß¡£
¢Ü.RNAi»¹±»ÓÃÀ´Ñо¿ÔÚ·¢Óý¹ý³ÌÖÐÆð×÷ÓõĻùÒò£¬Èç¿ÉÓÃRNAiÀ´×è¶ÏijЩ»ùÒòµÄ±í´ï£¬À´Ñо¿ËûÃÇÊÇ·ñÔÚÅßÌ¥¸Éϸ°ûµÄÔöÖ³ºÍ·Ö»¯¹ý³ÌÖÐÆäÆð׏ؼü×÷Óá£
2.4ʵÏÖ»ùÒòÇóýµÄÆäËûÔÀí¡£
³ýÉÏÊö¼¸ÖÖÒѾ±È½Ï³ÉÊì²¢ÇÒÆÕ±éʹÓÃÁ˵ĻùÒòÇóýÔÀíÍ⣬»¹ÓÐһЩ»ùÓÚÆäËûÔÀíµÄÇóý¼¼ÊõÕý´¦ÓÚÑо¿ºÍÍêÉÆ¹ý³ÌÖУ¬ÈçTFOs£¨Triple helix forming oligonucleotides£©Òýµ¼µÄ»ùÒòÇóýÊõ[16]ÒÔ¼°·´Òå¼¼ÊõÔÚ»ùÒòÇóý¼¼ÊõÖеÄÔËÓõÈ[17]¡£Ëæ×ÅÒÅ´«Ñ§£¬·Ö×ÓÉúÎïѧÀíÂ۵ķ¢Õ¹£¬ÐµĻùÒòÇóýÔÀíÒ²ÔÚ²»¶ÏµÄ·¢Ïֺͷ¢¾òÖС£
3£®»ùÒòÇóý¼¼ÊõµÄÓ¦Óü°Ç°¾°£º
¢Ù£®½¨Á¢ÉúÎïÄ£ÐÍ¡£ÔÚ»ùÒò¹¦ÄÜ£¬´úл;¾¶µÈÑо¿ÖÐÄ£ÐÍÉúÎïµÄ½¨Á¢·Ç³£ÖØÒª¡£»ùÒòÇóý¼¼Êõ¾Í³£³£ÓÃÓÚ½¨Á¢Ä³ÖÖÌØ¶¨»ùÒòȱʧµÄÉúÎïÄ£ÐÍ£¬´Ó¶ø½øÐÐÏà¹ØµÄÑо¿¡£ÕâЩģÐÍ¿ÉÒÔÊÇϸ°û£¬Ò²¿ÉÒÔÊÇÍêÕûµÄ¶¯Ö²Îï»ò΢ÉúÎï¸öÌå¡£×î³£¼ûµÄÊÇСÊ󣬼ÒÍá¢Öí¡¢Ï߳桢½ÍĸºÍÄâÄϽæµÈµÄ»ùÒòÇóýÄ£ÐÍÒ²³£¼ûÓÚ±¨µÀ¡£
¢Ú.¼²²¡µÄ·Ö×Ó»úÀíÑо¿ºÍ¼²²¡µÄ»ùÒòÖÎÁÆ¡£Í¨¹ý»ùÒòÇóý¼¼Êõ¿ÉÒÔÈ·¶¨Ìض¨»ùÒòµÄÐÔÖÊÒÔ¼°Ñо¿Ëü¶Ô»úÌåµÄÓ°Ïì¡£ÕâÎÞÂÛÊǶÔÁ˽⼲²¡µÄ¸ùÔ´»òÕßÊÇѰÕÒ»ùÒòÖÎÁƵİÐÄ¿±ê¶¼ÓÐÖØ´óµÄÒâÒå¡£
¢Û.ÌṩÁ®¼ÛµÄÒìÖÖÒÆÖ²Æ÷¹Ù¡£ÖÚËùÖÜÖª£¬Æ÷¹ÙÀ´Ô´Ï¡ÉÙÍùÍùÊÇÈËÌåÆ÷¹ÙÒÆÖ²µÄÒ»´óÖÆÔ¼ÒòËØ£¬¶ø´óÁ¿Á®¼ÛµÄÒìÖÖÉúÎïÈçÖíµÈµÄÆ÷¹ÙÈ´²»ÄÜÓÃÓÚÈËÌå¡£ÕâÊÇÒòΪÒìÔ´ÉúÎïµÄ»ùÒò»á²úÉúһЩÄÜÒýÆðÈËÌåÇ¿ÁÒÃâÒßÅųâµÄÒìÔ´·Ö×Ó£¬Èç¹ûÄܽ«²úÉúÕâЩÒìÔ´·Ö×ӵĻùÒòÇóý£¬ÄÇô¶¯ÎïµÄÆ÷¹Ù½«ÄÜÓÃÓÚÈËÌåµÄ¼²²¡ÖÎÁÆ£¬Õ⽫Ϊ»¼Õß´øÀ´¾ß´óµÄ¸£Òô¡£È磺PPL Therapeutics ¹«Ë¾ÓÚ1999 ÄêÒѳɹ¦µØÔÚÖíµÄÌåϸ°ûÖÐÓûùÒòÇóý¼¼ÊõÇóýÁ˦Á£1£¬3GT »ùÒò¡£Ê¹Ã¿Ö»Öí¶¼È±·¦²úÉúa£±££³°ëÈéÌÇ»ù×ªÒÆÃ¸µÄ»ùÒòµÄ£²¸ö¿½±´¡£ÕâЩøÔÚϸ°û±íÃæ²úÉúÒ»ÖÖÌÇ·Ö×Ó£¬ÈËÌåµÄÃâÒßϵͳ¿ÉÒÔÁ¢¼´±æÈϳöÕâÖÖÌÇ·Ö×ÓΪÒìÔ´ÐÔ£¬´Ó¶øÒý·¢³¬¼±ÐÔÃâÒßÅųⷴӦ¡£ÔÚȱ·¦ÕâÖÖøµÄÇé¿öÏ£¬³¬¼±ÐÔÅųⷴӦ¼´²»»áÔÙ·¢Éú[10]¡£
¢Ü. ÃâÒßѧÖеÄÓ¦Óá£Í¬ÒìÔ´Æ÷¹ÙÒÆÖ²ÏàËÆ£¬ÒìÔ´µÄ¿¹ÌåÓÃÓÚÈËÌåʱ»ò¶à»òÉÙ»áÓÐÒ»¶¨µÄÃâÒßÅų⣬ʹµÃÈËÓÿ¹ÌåÀàÒ©ÎïµÄÉú²úºÍÓ¦ÓÃÊÜ×è¡£¶øÈç¹û½«¶¯ÎïÃâÒß·Ö×Ó»ùÒòÇóý£¬»»ÒÔÈ˵ÄÏàÓ¦»ùÒò£¬ÄÇô½«²úÉúÈ˵Ŀ¹Ì壬´Ó¶ø½â¾öÈËÔ´¿¹ÌåµÄÉú²úÎÊÌâ¡£
¢Ý¸ÄÔìÉúÎï¡¢ÅàÓýеÄÉúÎïÆ·ÖÖ¡£Ï¸¾úµÄ»ùÒò¹¤³Ì¼¼ÊõÊDZ¾ÊÀ¼Í·Ö×ÓÉúÎïѧʷÉϵÄÒ»¸öÖØ´óÍ»ÆÆ£¬¶ø»ùÒòÇóý¼¼ÊõÔò¿ÉÄÜÊÇÒÅ´«¹¤³ÌÖеÄÁíÒ»ÖØ´ó·ÉÔ¾¡£ËüΪ¶¨Ïò¸ÄÔìÉúÎÅàÓýÐÂÐÍÉúÎïÌṩÁËÖØÒªµÄ¼¼ÊõÖ§³Ö¡£
4£®»ùÒòÇóý¼¼ÊõµÄȱÏÝ
Ëæ×Å»ùÒòÇóý¼¼ÊõµÄ·¢Õ¹£¬ÔçÆÚ¼¼ÊõÖеÄÐí¶à²»×ãºÍȱÏݶ¼ÒѾ½â¾ö£¬µ«»ùÒòÇóý¼¼ÊõʼÖÕ´æÔÚ×ÅÒ»¸öÄÑÒÔ¿Ë·þµÄȱµã£¬¼´ÇõôÒ»¸ö»ùÒò²¢²»Ò»¶¨¾ÍÄÜ»ñÖª¸Ã»ùÒòµÄ¹¦ÄÜ£¬ÆäÔÒò°üÀ¨£ºÒ»·½Ã棬Ðí¶à»ùÒòÔÚ¹¦ÄÜÉÏÊÇÈßÓàµÄ£¬ ÇõôÒ»¸ö
ÔÚ¹¦ÄÜÉÏÈßÓàµÄ»ùÒò£¬²¢²»ÄÜÔì³ÉÈÝÒ×ʶ±ðµÄ±íÐÍ£¬ÒòΪ»ùÒò¼Ò×åµÄÆäËû³ÉÔ±¿ÉÒÔÌṩͬÑùµÄ¹¦ÄÜ£»ÁíÒ»·½Ã棬¶ÔÓÚijЩ±ØÐè»ùÒò£¬Çóýºó»áÔì³Éϸ°ûµÄÖÂËÀÐÔ£¬Ò²¾ÍÎÞ·¨¶ÔÕâЩ±ØÐè»ùÒò½øÐÐÏàÓ¦µÄÑо¿ÁË¡£
²Î¿¼ÎÄÏ×£º
1£®ÍõÓÖºì »ùÒòÇóý¼¼ÊõµÄÓ¦ÓÃÏÖ×´Ó뷢չǰ¾° ¹úÍâҽѧ 1999 26-5
2£®Muller,-U. Ten years of gene targeting: targeted mouse mutants, from vector
design to phenotype analysis. Mech-Dev. 1999 Apr; 82(1-2): 3-21
3£®Ledermann,-B. Embryonic stem cells and gene targeting. Exp-Physiol. 2000 Nov;
85(6): 603-13
4. ARMIN HALLMANN*, ANNETTE RAPPEL, AND MANFRED SUMPER Gene replacement by homologous recombination in the multicellular green alga Volvox carteri
Proc. Natl. Acad. Sci. USA Vol. 94, pp. 7469¨C7474, July 1997
5.Thomas P. homologous recombination in human ES cell Nature publish on line 2003 10 Feb
6£®ÁõµÂÅà·½¸£µÂ »ùÒòÇóý ÉúÀí¿ÆÑ§½øÕ¹ 1995 26£1
7. Nelson RJ, Young KA. Behavior in mice with targeted disruption of
single genes. Neurosci Biobehav Rev 1998;22:453¡À62.
8. Andrew Holmes Targeted gene mutation approaches to the study of anxiety-like
behavior in mice Neuroscience and Biobehavioral Reviews 25 (2001) 261¡À273
9£®Hasty P et al; Nature;1991;350;243
10.yunfengli »ùÒòÇóý¼¼ÊõµÄ×îнøÕ¹ ¶¡ÏãÔ°µç×ÓÆÚ¿¯2003£12
11. ³ÂÆä¾ü£¬Ð¤Óñ÷µÈ Ö²Î﹦ÄÜ×éÑо¿ÖеĻùÒòÇóý¼¼Êõ Ö²ÎïÉúÀíѧͨѶ 2004-1£¬40£º121¡«126
12. U. Klinner *, B. Sch€afer Genetic aspects of targeted insertion mutagenesis in yeasts FEMS Microbiology Reviews 28 (2004) 201¨C223
13. Joel S. Bedford∗, Howard L. Liber Applications of RNA interference for studies in DNA damage processing, genome stability, mutagenesis, and cancer Seminars in Cancer Biology 13 (2003) 301¨C308
14£®Georg Mellitzera,b, Marc Halloneta, Lan Chena, Siew-Lan Anga,Spatial and temporal ¡®knock down¡¯ of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos Mechanisms of Development 118 (2002) 57¨C63
15. H_akan Thonberg,* Camilla C. Sch_eele, Cecilia Dahlgren, and Claes Wahlestedt Characterization of RNA interference in rat PC12 cells: requirement of GERp95 Biochemical and Biophysical Research Communications 318 (2004) 927¨C934
16. Alokes Majumdar1, Alexander Khorlin2, Natalia Dyatkina2Targeted gene knockout mediated by triple helix forming oligonucleotides nature 1998
17. Roberto P. Stock1, Alejandro Olvera1, Ricardo S¨¢nchez1, Inhibition of gene expression in Entamoeba histolytica with antisense peptide
nucleic acid oligomers Nature Publishing Group 2001


